Literature DB >> 24150908

Tracking motor impairments in the progression of Huntington's disease.

Jeffery D Long1, Jane S Paulsen, Karen Marder, Ying Zhang, Ji-In Kim, James A Mills.   

Abstract

The Unified Huntington's Disease Rating Scale is used to characterize motor impairments and establish motor diagnosis. Little is known about the timing of diagnostic confidence level categories and the trajectory of motor impairments during the prodromal phase. Goals of this study were to estimate the timing of categories, model the prodromal trajectory of motor impairments, estimate the rate of motor impairment change by category, and provide required sample size estimates for a test of efficacy in clinical trials. In total, 1010 gene-expanded participants from the Neurobiological Predictors of Huntington's Disease (PREDICT-HD) trial were analyzed. Accelerated failure time models were used to predict the timing of categories. Linear mixed effects regression was used to model the longitudinal motor trajectories. Age and length of gene expansion were incorporated into all models. The timing of categories varied significantly by gene expansion, with faster progression associated with greater expansion. For the median expansion, the third diagnostic confidence level category was estimated to have a first occurrence 1.5 years before diagnosis, and the second and first categories were estimated to occur 6.75 years and 19.75 years before diagnosis, respectively. Motor impairments displayed a nonlinear prodromal course. The motor impairment rate of change increased as the diagnostic confidence level increased, with added acceleration for higher progression scores. Motor items can detect changes in motor impairments before diagnosis. Given a sufficiently high progression score, there is evidence that the diagnostic confidence level can be used for prodromal staging. Implications for Huntington's disease research and the planning of clinical trials of efficacy are discussed.
© 2013 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; cohort studies; movement disorders; neurodegenerative disease; predictive testing

Mesh:

Year:  2013        PMID: 24150908      PMCID: PMC4219558          DOI: 10.1002/mds.25657

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  33 in total

1.  A joint model for nonlinear longitudinal data with informative dropout.

Authors:  Chuanpu Hu; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

2.  CAG repeat number governs the development rate of pathology in Huntington's disease.

Authors:  J B Penney; J P Vonsattel; M E MacDonald; J F Gusella; R H Myers
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

3.  Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.

Authors:  B K Puri; B R Leavitt; M R Hayden; C A Ross; A Rosenblatt; J T Greenamyre; S Hersch; K S Vaddadi; A Sword; D F Horrobin; M Manku; H Murck
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

4.  Saccades in presymptomatic and early stages of Huntington disease.

Authors:  T Blekher; S A Johnson; J Marshall; K White; S Hui; M Weaver; J Gray; R Yee; J C Stout; X Beristain; J Wojcieszek; T Foroud
Journal:  Neurology       Date:  2006-07-19       Impact factor: 9.910

5.  Preparing for preventive clinical trials: the Predict-HD study.

Authors:  Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner
Journal:  Arch Neurol       Date:  2006-06

6.  The association of CAG repeat length with clinical progression in Huntington disease.

Authors:  A Rosenblatt; K-Y Liang; H Zhou; M H Abbott; L M Gourley; R L Margolis; J Brandt; C A Ross
Journal:  Neurology       Date:  2006-04-11       Impact factor: 9.910

7.  Unified Huntington's disease rating scale: a follow up.

Authors:  S Siesling; J P van Vugt; K A Zwinderman; K Kieburtz; R A Roos
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

8.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

9.  Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.

Authors: 
Journal:  Neurology       Date:  2006-02-14       Impact factor: 9.910

10.  Huntington's disease: clinical correlates of disability and progression.

Authors:  N Mahant; E A McCusker; K Byth; S Graham
Journal:  Neurology       Date:  2003-10-28       Impact factor: 9.910

View more
  28 in total

1.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Authors:  Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker
Journal:  Lancet Neurol       Date:  2014-11-03       Impact factor: 44.182

2.  Onset of Huntington's disease: can it be purely cognitive?

Authors:  Jane S Paulsen; Jeffrey D Long
Journal:  Mov Disord       Date:  2014-08-20       Impact factor: 10.338

3.  Validation of a prognostic index for Huntington's disease.

Authors:  Jeffrey D Long; Douglas R Langbehn; Sarah J Tabrizi; Bernhard G Landwehrmeyer; Jane S Paulsen; John Warner; Cristina Sampaio
Journal:  Mov Disord       Date:  2016-11-28       Impact factor: 10.338

4.  HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with huntington's disease.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Kelvin L Chou; Rebecca E Ready; David Cella; Michael K McCormack; Jennifer A Miner; Praveen Dayalu
Journal:  Mov Disord       Date:  2019-11-14       Impact factor: 10.338

5.  Gradient Boosted Trees for Corrective Learning.

Authors:  Baris U Oguz; Russell T Shinohara; Paul A Yushkevich; Ipek Oguz
Journal:  Mach Learn Med Imaging       Date:  2017-09-07

6.  Dynamic Prediction of Motor Diagnosis in Huntington's Disease Using a Joint Modeling Approach.

Authors:  Kan Li; Erin Furr-Stimming; Jane S Paulsen; Sheng Luo
Journal:  J Huntingtons Dis       Date:  2017

7.  Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures.

Authors:  Noelle E Carlozzi; Rebecca E Ready; Samuel Frank; David Cella; Elizabeth A Hahn; Siera M Goodnight; Stephen G Schilling; Nicholas R Boileau; Praveen Dayalu
Journal:  Mov Disord       Date:  2017-05-27       Impact factor: 10.338

8.  The impact of oculomotor functioning on neuropsychological performance in Huntington disease.

Authors:  Janessa O Carvalho; Jeffrey D Long; Holly J Westervelt; Megan M Smith; Jared M Bruce; Ji-In Kim; James A Mills; Jane S Paulsen
Journal:  J Clin Exp Neuropsychol       Date:  2016       Impact factor: 2.475

9.  Responsiveness to Change Over Time: An Examination of the Neuro-QoL Social Function Measures in Persons with Huntington's Disease.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Elizabeth A Hahn; Stacey K Barton; David Cella; Michael K McCormack; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2020

10.  Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden.

Authors:  Mandi Musso; Holly James Westervelt; Jeffrey D Long; Erin Morgan; Steven Paul Woods; Megan M Smith; Wenjing Lu; Jane S Paulsen
Journal:  J Int Neuropsychol Soc       Date:  2015-01       Impact factor: 2.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.